Abcam Buys MitoSciences for $6M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein research tools firm Abcam today announced it has completed its $6 million buy of MitoSciences.

Abcam, based in Cambridge, UK, paid $4.2 million in cash and issued $1.8 million of Abcam shares at $397.1 pence per share as part of the deal. The purchase will enhance the range of products available to its customers, Abcam said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.